Seres Therapeutics, Inc. (MCRB) — SEC Filings
Seres Therapeutics, Inc. (MCRB) — 45 SEC filings. Latest: 8-K (May 5, 2026). Includes 29 8-K, 6 10-Q, 3 DEFA14A.
View Seres Therapeutics, Inc. on SEC EDGAR
Overview
Seres Therapeutics, Inc. (MCRB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: Seres Therapeutics, Inc. (MCRB) reported a net income from continuing operations of $21.03 million for the nine months ended September 30, 2025, a significant improvement from a net loss of $110.13 million in the same period of 2024. This turnaround was primarily driven by a substantial gain of $79.
Sentiment Summary
Across 45 filings, the sentiment breakdown is: 2 bullish, 3 bearish, 38 neutral, 2 mixed. The dominant filing sentiment for Seres Therapeutics, Inc. is neutral.
Filing Type Overview
Seres Therapeutics, Inc. (MCRB) has filed 29 8-K, 6 10-Q, 3 DEFA14A, 2 10-K, 1 SC 13D/A, 3 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (45)
Risk Profile
Risk Assessment: Of MCRB's 36 recent filings, 4 were flagged as high-risk, 14 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0.35M |
| Net Income | $21.03M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $47.64M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- David A. Carpenter, Esq.
- Abigail P. Johnson
Industry Context
The biotechnology industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Seres Therapeutics focus on developing novel therapies, often requiring substantial capital investment and facing intense competition. Success is heavily dependent on clinical trial outcomes and regulatory approvals.
Top Tags
financial-condition (7) · filing (5) · sec-filing (5) · 8-K (4) · operations (4) · 10-Q (3) · proxy-statement (3) · pharmaceuticals (3) · financials (3) · corporate-governance (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income from Continuing Operations | $21.03M | For the nine months ended September 30, 2025, a significant improvement from a $110.13M loss in 2024. |
| Gain on Sale of VOWST Business | $79.59M | Primary driver of the net income turnaround for the nine months ended September 30, 2025. |
| Cash and Cash Equivalents | $47.64M | As of September 30, 2025, up from $30.79M at December 31, 2024, improving liquidity. |
| Net Cash Provided by Operating Activities | $15.83M | For the nine months ended September 30, 2025, a positive shift from a negative cash flow in the prior year. |
| Research and Development Expenses | $37.38M | For the nine months ended September 30, 2025, a decrease from $51.76M in 2024, reflecting cost reduction. |
| Shares Outstanding | 9,046,519 | As of October 31, 2025, indicating the current share count after the reverse stock split. |
| Total Revenue | $0.35M | For the nine months ended September 30, 2025, solely from grant revenue, indicating limited product sales. |
| Operating Expense Reduction | 19% | Total operating expenses decreased from $92.48M in 2024 to $74.95M in 2025. |
| Net Loss for Q2 2025 | $60.5M | Increased from $45.2M in Q2 2024 |
| Research and Development Expense for Q2 2025 | $35.1M | Decreased from $40.3M in Q2 2024 |
| General and Administrative Expense for Q2 2025 | $18.7M | Decreased from $20.1M in Q2 2024 |
| Cash and Cash Equivalents as of June 30, 2025 | $120.3M | Decreased from $185.6M at December 31, 2024 |
| Date of Transition Services Agreement | 2025-07-01 | Subsequent event with NESA |
| Reporting Period | Q1 2025 | The period covered by the 10-Q filing. |
| As of Date | 2025-03-31 | The specific date for which financial information is reported. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant, albeit potentially fluctuating, passive investment in Seres Therapeutics, Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Seres Therapeutics, Inc. (MCRB)?
Seres Therapeutics, Inc. has 45 recent SEC filings from Jan 2024 to May 2026, including 29 8-K, 6 10-Q, 3 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MCRB filings?
Across 45 filings, the sentiment breakdown is: 2 bullish, 3 bearish, 38 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Seres Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Seres Therapeutics, Inc. (MCRB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Seres Therapeutics, Inc.?
Key financial highlights from Seres Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MCRB?
The investment thesis for MCRB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Seres Therapeutics, Inc.?
Key executives identified across Seres Therapeutics, Inc.'s filings include David A. Carpenter, Esq., Abigail P. Johnson.
What are the main risk factors for Seres Therapeutics, Inc. stock?
Of MCRB's 36 assessed filings, 4 were flagged high-risk, 14 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Seres Therapeutics, Inc.?
Recent forward-looking statements from Seres Therapeutics, Inc. include guidance on {"claim":"FMR LLC will maintain a significant, albeit potentially fluctuating, passive investment in Seres Therapeutics,.